Evidence map›Paper›PMID 42084379›Full record

ArticleJournal of virology2026

A chimeric trivalent Echovirus vaccine designed by loop substitution elicits cross-neutralizing immunity against serotypes 11, 18, and 30.

Shuai Jiang, Jiaqi Cui, Tao Sun, Jiahuang Li, Heming Li, Tianlun Chen, Jiahui Wu, Zhenhua Zheng, Jianbo Xia, Chunchen Wu and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuai Jiang *School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.ORCID 0009-0007-4317-1845
Jiaqi Cui *School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Tao SunSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Jiahuang LiSchool of Biopharmacy, China Pharmaceutical University, Nanjing, China.ORCID 0000-0003-3513-4159
Heming LiSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Tianlun ChenSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Jiahui WuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
Zhenhua ZhengCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.ORCID 0000-0002-4117-9364
Jianbo XiaDepartment of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-8912-9921
Chunchen WuDepartment of Laboratory Medicine, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0002-6888-213X
Jie WuSchool of Life Science and Technology, China Pharmaceutical University, Nanjing, China.ORCID 0000-0002-3398-1461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Echoviruses, members of the Enterovirus B genus in the Picornaviridae family, comprise numerous serotypes that frequently cause aseptic meningitis, myocarditis, and severe neonatal infections. The coexistence of multiple antigenically distinct serotypes poses a significant challenge for vaccine development, underscoring the clinical need for a broad-spectrum multivalent vaccine. In this study, we focused on three prevalent serotypes-Echovirus 11 (E11), 18 (E18), and 30 (E30)-as representative models to explore multivalent vaccine design. We first predicted and experimentally identified dominant B-cell epitopes within the VP1 proteins of these viruses. Guided by these analyses, a chimeric trivalent antigen (VP1-III) was rationally constructed by substituting epitope-containing loops from E18 and E30 into the VP1 backbone of E11. Structural modeling confirmed that VP1-III preserved native VP1 conformation while displaying multitype epitopes. Both VP1-III recombinant protein and mRNA-lipid nanoparticle vaccines induced potent immunogenicity in mice, characterized by cross-neutralizing antibodies and Th1-biased cellular responses. These findings support structure-guided epitope integration as a promising strategy for developing broadly protective multivalent Echovirus vaccines.IMPORTANCEEchoviruses cause widespread outbreaks and severe neonatal disease, yet vaccine development remains limited by extensive antigenic diversity among serotypes. Here, we rationally engineered a chimeric trivalent VP1 antigen by grafting dominant epitopes from E11, E18, and E30 through structure-guided loop substitution. Both recombinant protein and mRNA formulations induced robust cross-neutralizing and Th1-biased immune responses in mice, demonstrating that strategic epitope substitution can effectively overcome serotype barriers and providing a promising path toward broad-spectrum Echovirus vaccines.

Indexed as

Antibodies, NeutralizingEchovirus InfectionsEnterovirus B, HumanViral VaccinesAnimalsAntibodies, ViralCapsid ProteinsCross ReactionsEpitopes, B-LymphocyteFemaleHumansMiceMice, Inbred BALB CProtein Subunit VaccinesSerogroupAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsEpitopes, B-LymphocyteProtein Subunit VaccinesViral VaccinesEchovirusEnterovirusloop substitutionmRNA vaccinetrivalent vaccine

Identifiers

PMID42084379
PMCPMC13289168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.